Hiroaki Sano

Mr. Hiroaki Sano

Auto-generated profile, based on publicly available information

Mr. Hiroaki Sano


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2025 in Medicina
Verified
Journal Article
Open access
PDF file
IHIWASAKI HIDEKI
IWASAKI HIDEKI
GSGulam Mohiyuddin Shirol
Gulam Mohiyuddin Shirol
TMTomoji Maeda
Tomoji Maeda
MWMineo Christopher Watanabe
Mineo Christopher Watanabe
TTTokuko Takajo
Tokuko Takajo
Yoshikazu MatsudaYoshikazu Matsuda
Yoshikazu Matsuda
Background and Objectives: Kumazasa extract (KZExt) is a food product obtained by steam extraction of Kumazasa (Sasa senanensis and Sasa kurilensis) leaves under high temperature and pressure. It contains abundant polyphenols, including trans-p-coumaric acid and ferulic acid, as well as xylooligosaccharides. In this study, we investigated the antibacterial, anti-viral, and anti-inflammatory effects of KZExt in vitro and in vivo. Materials and Methods: The anti-oxidant, antibacterial, and anti-viral effects of KZExt were assessed in vitro. Anti-oxidant activity was evaluated based on the scavenging of •OH, •O2− and 1O2. Antibacterial effects were assessed by determining the minimum inhibitory concentration (MIC) using a microdilution method. Anti-influenza activity was measured via plaque formation in MDCK cells. Anti-inflammatory effects were assessed by measuring interleukin (IL)-1β inhibition in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. In vivo, KZExt was administered once (30 min before) in a formalin-induced inflammation model to evaluate pain-related behavior. In the LPS-induced inflammation model, KZExt was administered for five days before LPS injection. Behavioral changes and cytokine levels were assessed 24 h later via the open field test and cytokine quantification. Results: In vitro, KZExt showed antibacterial, anti-influenza, and anti-oxidant effects, and suppressed LPS-induced IL-1β production. In vivo, it significantly reduced the second phase of formalin-induced pain behavior. In the LPS model, although behavioral changes were unaffected, KZExt suppressed IL-6 and interferon-γ production. Conclusions: The antibacterial, anti-viral, and anti-inflammatory effects of KZExt were confirmed in vitro and in vivo. Notably, the anti-inflammatory effect suggests potential immunomodulatory activity. These findings indicate that KZExt may help suppress smoldering inflammation and inflammation associated with various diseases through its combined antibacterial, anti-viral, and immunomodulatory actions.